figshare
Browse
12885_2021_8031_MOESM1_ESM.docx (12.22 kB)

Additional file 1 of Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Download (12.22 kB)
journal contribution
posted on 2021-03-24, 04:34 authored by Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. de Vos-Geelen, B. M. Zonderhuis, M. Y. V. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp
Additional file 1: Supplementary file PREOPANC-2 trial.

Funding

ZonMw (NL) KWF Kankerbestrijding

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    NeoadjuvantFOLFIRINOXGemcitabineChemoradiotherapyLocalized pancreatic cancerIntention-to-treatRandomized controlled trialOverall survivalQuality of life

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC